Intensified Tx Doesn't Up Survival in Tuberculous Meningitis

This article originally appeared here.
Share this content:
Intensified Tx Doesn't Up Survival in Tuberculous Meningitis
Intensified Tx Doesn't Up Survival in Tuberculous Meningitis

FRIDAY, Jan. 15, 2016 (HealthDay News) -- For patients with tuberculous meningitis, intensified antituberculosis treatment is not associated with higher survival than standard treatment, according to a study published in the Jan. 14 issue of the New England Journal of Medicine.

A. Dorothee Heemskerk, M.D., from the Oxford University Clinical Research Unit in the United Kingdom, and colleagues performed a randomized placebo-controlled trial involving HIV-infected adults and uninfected adults with a clinical diagnosis of tuberculous meningitis. A standard nine-month antituberculosis regimen (including 10 mg/kg body weight of rifampin/day) was compared with an intensified regimen that included higher-dose rifampin and levofloxacin. A total of 817 patients were enrolled (349 HIV-infected); 409 and 408 were randomized to the standard regimen and intensified treatment, respectively.

The researchers found that 113 patients in the intensified-treatment group and 114 in the standard-treatment group died during the nine months after follow-up (hazard ratio, 0.94; 95 percent confidence interval, 0.73 to 1.22). No evidence of a significant differential effect of intensified treatment was seen in the overall population, or in any subgroups, except possibly for patients infected with isoniazid-resistant Mycobacterium tuberculosis. Secondary outcomes did not differ significantly between the treatment groups. There was no significant between-group difference in the overall number of adverse events leading to treatment interruption (P = 0.08).

"Intensified antituberculosis treatment was not associated with a higher rate of survival among patients with tuberculous meningitis than standard treatment," the authors write.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths